RxDoctor Payments Data

Bryan Beck, MD

Cardiovascular Disease · Cape Girardeau, MONPI 1720018179

Payments from drug & device makers

$10,344in general payments, 2019–2025

Across 452 payments — averaging $22.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Johnson & Johnson$1K
  • Boehringer Ingelheim$635
  • Novartis$469
  • Edwards Lifesciences$378
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$341
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$2,03720%
  • Food & beverage$8,20879%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,344 in reported general payments places this provider in the 70th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$372,780
Medicare patients
1,677
Services billed
7,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban1,026$797,968
EliquisApixaban567$461,490
EntrestoSacubitril/Valsartan510$436,787
JardianceEmpagliflozin159$112,976
FarxigaDapagliflozin Propanediol111$84,337
Repatha SureclickEvolocumab33$18,964
Metoprolol Succinate1,353$18,272
Repatha SyringeEvolocumab17$13,328
Diltiazem 24hr Er (Cd)Diltiazem Hcl376$11,197
Flecainide Acetate262$9,200
Carvedilol1,410$8,092
Amiodarone Hcl544$8,030
Ranolazine ErRanolazine134$7,759
Prasugrel Hcl103$7,350
Isosorbide Dinitrate88$5,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,012$797,9681,026 claims
PfizerEliquis$95$461,490567 claims
NovartisEntresto$469$436,787510 claims
Boehringer IngelheimJardiance$635$112,976159 claims
AstraZenecaFarxiga$75$84,337111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →